|
deCODE genetics Incorporated, founded in 1996 and based in Reykjavik, Iceland, is a biopharmaceutical company that employs human genetics analysis technologies in developing drugs and diagnostics for common diseases. The firm has isolated genes associated with cardiovascular diseases and cancer. Information is employed in developing drug targets. deCODE genetics' DNA testing laboratory, which has earned CLIA certification, conducts drug discovery research on 50 common human diseases. The firm's deCODE T2 (TM) novel, DNA-based reference laboratory test detects a genetic risk factor for type 2 diabetes. DeCODE AF (TM) detects two single nucleotide polymorphisms (SNPs) associated with atrial fibrillation risks. The deCODE MI (TM) test identifies risk factors for myocardial infarction (MI). deCODE genetics offers clients genotyping, structural biology research, chemistry, clinical development, and biorepository services. Clinical development services are offered through the Encode subsidiary. deCODE genetics has formed alliances with Illumina Incorporated, Roche, and Merck. The firm is developing new treatments for arterial thrombosis, stroke, inflammation, pain, obesity, schizophrenia, and other diseases.
|